Skip to Content

Grant Support

NIH-NIAID (UM1 AI114271), “Inner City Asthma Consortium (ICAC)” (2002-2021).  Gern, Co-PI    

NIH-NIAID (T32 AI007635), “Wisconsin allergy and immunology research training program” (2000-2020).  Gern, PI

NIH-NIAID and Boston Children’s Hospital (R01 AI108588), “Viral persistence & the microbiome in bronchiolitis and risk of recurrent wheeze” (2015-2019).  Gern, Co-Investigator

NIH-NIAID and Massachusetts General Hospital (R01 AI114552), “Infant specific-IgE, rhinovirus-C bronchiolitis, and incident asthma in MARC-35” (2014-2019).  Gern, Co-Investigator

Wisconsin Partnership Program, “Zooming in on childhood asthma: disease causality and personalized medicine” (2015-2018).  Gern, Co-Investigator

NIH-NHLBI (P01 HL070831), “Childhood Origins of Asthma (COAST): rhinovirus infections in children and adolescents” (2002-2018).  Gern, Project II Leader

NIH-NIAID (U19 AI104317), “Mechanisms and environmental determinants of rhinovirus illness severity” (2013-2018). Gern, PI

NIH-NIAID (R01 AI097172), “Sinusitis in children: viruses and the nasopharyngeal microbiome” (2011-2016).  Gern, Co-Investigator


Completed Grants

NIH-NIAID and University of California-San Francisco (P01 AI089473), “Virus/microbe interactions and asthma” (2014-2015).  Gern, Co-Investigator

NIFA-USDA, “Preventing food protein allergic reactions via conjugation with polysaccharides” (2011-2015).  Gern, Co-Investigator

Schering-Plough Corporation, “Selective induction of pro-inflammatory mediators in asthmatic subjects following experimental infection with HRV-16” (2012-2013).  Gern, PI

NIH-NIAID (U19 AI070503), "Mechanisms of rhinovirus-induced exacerbations of asthma” (2006-2013).  Gern, PI

AstraZeneca, “The effect of 'adjustable' treatment with budesonide/formoterol on rhinovirus provoked exacerbations of asthma D-Code-D589BN00028-P” (2008-2011).  Gern, PI

NIH-NIAID and University of Virginia (U19 AI070364), “Using the experimental virus challenge model to decipher the asthmatic response to rhinovirus” (2008-2010).  Gern, Co-Investigator

NIH-NIAID (R01 HL080072), “T regulatory cells and childhood asthma” (2004-2010).  Gern, PI

NIH-NIAID and Baylor College of Medicine (U19 AI070412), "Rhinoviral proteinases in experimental asthma: development of a method for preparation of LPS-free rhinoviral proteases" (2009).  Gern, Co-Investigator

NIH-NHLBI (R01 HL080412), “Viral Induced Asthma Exacerbations (VIAX) ” (2005-2009).  Gern, Co-Investigator

NIH-NIAID (U19 AI070503, supplement), “Plasmid-based HRV-16 Human Inoculum” (2007-2008).  Gern, PI

NIH and University of Texas-San Antonio, "Reverse genetic approach to produce type-16 rhinovirus in GMF facility: mechanisms of rhinovirus-induced exacerbations of asthma" (2007-2008).  Gern, Co-Investigator

Merck, Inc, “Effect of montelukast on experimentally-induced RV16 infection in volunteers with mild asthma” (2005-2008).  Gern, PI

Proctor & Gamble Company, “Common cold research” (2000-2008).  Gern, PI

NIH-NCRR (M01 RR003186) “General clinical research center” (2005-2007). Gern, Assistant Director for Pediatrics and Medical Education for the University of Wisconsin-Madison GCRC

GlaxoSmithKline, “Inoculation of volunteers with a new safety tested inoculum of type-16 human rhinovirus” (2004-2007).  Gern, PI.

NIH-NIAID (P01 AI050500), “Mechanisms of virus-induced asthma” (2001-2007).  Gern, PI

NIH-NIMH (R01 MD066073), “Anxiety & inflammatory correlates in youth with eczema” (2004-2006). Gern, Co-Investigator

Aguoron Pharmaceuticals, Inc., “A phase II, randomized, placebo-controlled, double-blind, multicenter study of ruprintrivir (ag7088) nasal spray, 0.2% solution for the treatment of natural rhinovirus infection in adults A433-1001” (2002-2005).  Gern, PI.

Perlan Therapeutics, Inc., “Pre-clinical studies” (2001).  Gern, PI


Last updated: 08/17/2015
webmaster [at] pediatrics [dot] wisc [dot] edu
Copyright © 2015 The Board of Regents of the University of Wisconsin System